Strong long-term results with CERAMENT®G for severe open fractures – study from Manchester University Hospital - Investor

BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company’s antibiotic-eluting bone graft CERAMENT G.

The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection.

“Our clinical experience suggests that CERAMENT G is an important adjuvant to consider in complex limb reconstruction, laying the ground for improved functional outcomes for the patient” said Dr. Anand Pillai, consultant orthopedic and trauma surgeon.

The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.